Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular 3 genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency (CROSBI ID 160409)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Karačić, Iva ; Meili, David ; Sarnavka, Vladimir ; Heintz, Caroline ; Thöny, Beat ; Petković Ramadža, Danijela ; Fumić, Ksenija ; Mardešić, Duško ; Barić, Ivo ; Blau, Nenad Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular 3 genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency // Molecular genetics and metabolism, 97 (2009), 3; 165-171. doi: 10.1016/j.ymgme.2009.03.009

Podaci o odgovornosti

Karačić, Iva ; Meili, David ; Sarnavka, Vladimir ; Heintz, Caroline ; Thöny, Beat ; Petković Ramadža, Danijela ; Fumić, Ksenija ; Mardešić, Duško ; Barić, Ivo ; Blau, Nenad

engleski

Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular 3 genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency

Specific mutations in the gene encoding phenylalanine hydroxylase (PAH), located on chromosome 12q22-24.1, are linked to tetrahydrobiopterin (BH4 ; sapropterin)-responsive phenylketonuria (PKU). Diagnosis is usually done through the newborn screening for PKU, followed by a BH4 loading test. So far, more than 60 mutant alleles, presenting with a substantial residual PAH activity (average 47%), were identified in more than 500 patients worldwide. We investigated the predictive value of BH4-responsive PAH mutations in Croatian population. From a group of 127 PKU patients, 62 were selected (based on the genotype) as potentially BH4-responsive and 39 loaded with BH4 (20 mg/kg). The overall frequency of BH4-responsiveness (>30% blood phenylalanine reduction within 24 h) was 36% (14 out of 39 patients with 23 different genotypes), significantly less than expected. The best responders were patients with mild hyperphenylalaninemia (4/4 ; 100%), followed by mild PKU (8/9 ; 89%), and classical PKU (2/26 ; 8%). The most common BH4-responsive genotypes were p.E390G/p.R408W and p.P281L/p.E390G. These genotypes correspond for approximately >30% residual PAH activity. The p.E390G mutation was 100% associated with BH4-responsiveness, regardless of the second allele (p.R408W, p.P281L, p.F55Lfs, p.L249P). With regard to the predicted relative PAH activity of recombinantly expressed mutant alleles, there was a significant (p < 0.002) difference between BH4-responders and non-responders. In a general Croatian PKU population, disease-causing mutations were identified on 226 alleles (99%). There were 35 different mutations: 21 missense, 8 splice site, 3 nonsense, 2 single nucleotide deletions, and 1 in-frame deletion. Four mutations are reported for the first time: p.E76D, p.L333P, p.G346E, and IVS8-2A > G. Five mutations accounted for over two-thirds of investigated alleles: p.L48S, p.R261Q, p.P281L, p.E390G, and p.R408W. Thus, the Croatian PKU population seems to be more homogenous than some other Mediterranean or Central European populations. This study reveals the importance of a full genotype for the prediction of BH4-responsiveness. In contrast to previous assumption and with exception of the p.E390G mutation, single allele mutations are not reliable for the selection of potential PKU candidates for pharmacological therapy with BH4.

PKU; phenylketonuria; genotype; BH4-responsiveness; sapropterin

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

97 (3)

2009.

165-171

objavljeno

1096-7192

10.1016/j.ymgme.2009.03.009

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost